相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1
Eric J. Lowe et al.
BLOOD (2021)
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
Soumya S. Rajan et al.
ONCOGENE (2020)
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
Kelly C. Goldsmith et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial
Alain P. Algazi et al.
NATURE MEDICINE (2020)
Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia
Himalee S. Sabnis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Pierre Laneuville
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
Marketa Bloomfield et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2018)
ALK in Neuroblastoma: Biological and Therapeutic Implications
Ricky M. Trigg et al.
CANCERS (2018)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma
Priyanka Verma et al.
SOUTH ASIAN JOURNAL OF CANCER (2017)
Anaplastic large cell lymphoma in paediatric and young adult patients
Suzanne D. Turner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib
Carlo Gambacorti-Passerini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Eco-evolution of cancer resistance
Giannoula L. Klement
SCIENCE TRANSLATIONAL MEDICINE (2016)
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Pedro M. Enriquez-Navas et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
Youngjoo Lee et al.
ONCOTARGET (2016)
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Amit Dipak Amin et al.
CANCER RESEARCH (2015)
Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma
Kelley V. Foyil et al.
CANCER JOURNAL (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lessons from Applied Ecology: Cancer Control Using an Evolutionary Double Bind
Robert A. Gatenby et al.
CANCER RESEARCH (2009)
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma
Christine Damm-Welk et al.
BLOOD (2007)
Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - A report from the French Society of Pediatric Oncology
L Brugieres et al.
ANNALS OF ONCOLOGY (2000)
分享论文
